Roche advances its open diabetes management ecosystem by integrating continuous glucose monitoring data to drive personalised therapy decisions
Roche advances its open diabetes management ecosystem by integrating continuous glucose monitoring data to drive personalised therapy decisions |
[26-September-2018] |
- The expansion of the partnership with Senseonics is the next step in integrating the long-term Eversense® Continuous Glucose Monitoring (CGM) system with Roche's suite of digital diabetes management solutions. - People with diabetes and their physicians will be able to view real-time glucose information and related data both on Roche's apps and web-based solutions in addition to the Eversense app. - This integration will unlock data access for users to a consolidated view of therapy-relevant information, thus supporting improved therapy decisions. BASEL, Switzerland, Sept. 26, 2018 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has signed a non-exclusive data integration agreement with Senseonics Incorporated, expanding its partnership. Under the terms of the agreement, both partners aim to implement the next step in data integration of the long-term Eversense Continuous Glucose Monitoring (CGM) system with Roche's suite of digital diabetes management solutions. This integration will allow for the real-time CGM data to be synchronised so Eversense users and their physicians will be able to review glucose values as well as related data online and on their mobile phones e.g. via the mySugr app or Accu-Chek Smart Pix. The initial data integration is planned to be available to users beginning 2019. "Expanding our longstanding relationship with Senseonics by incorporating data generated via the Eversense and Eversense XL CGM sensors into our digital solutions is an important step in moving our open ecosystem forward. Doing so, we continue to embrace our vision to bring innovation by means of truly integrated diabetes management solutions to the market, empowering people with diabetes to confidently manage their therapy routines every day and helping them experience true relief," says Marcel Gmuender, Global Head of Roche Diabetes Care. "Partnering with Roche and being part of its open ecosystem for personalised diabetes management is a good fit with our strategy of giving people with diabetes the tools to use valuable health data for making actionable and informed therapy decisions," states Dr. Tim Goodnow, President and, CEO of Senseonics. About Roche Diabetes Care About Roche For more information please contact: - Ute Volkmann (ute.volkmann@roche.com) - Soo-Jin Pak (soo-jin.pak@roche.com) Logo - https://mma.prnewswire.com/media/709962/Roche_Logo.jpg | ||
Company Codes: OTC-BB:RHHBY, Swiss:RO, OTC-PINK:RHHBY, Swiss:ROG, OTC-QX:RHHBY |
© 2018 PR Newswire. All Rights Reserved.